Adverum Biotechnologies Inc (ADVM)
11.30
+0.15
(+1.35%)
USD |
NASDAQ |
Apr 19, 16:00
11.30
0.00 (0.00%)
After-Hours: 18:08
Adverum Biotechnologies Free Cash Flow (Quarterly): -21.52M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -21.52M |
September 30, 2023 | -24.41M |
June 30, 2023 | -23.28M |
March 31, 2023 | -22.50M |
December 31, 2022 | -18.66M |
September 30, 2022 | -32.63M |
June 30, 2022 | -35.31M |
March 31, 2022 | -33.30M |
December 31, 2021 | -30.17M |
September 30, 2021 | -31.52M |
June 30, 2021 | -37.56M |
March 31, 2021 | -23.71M |
December 31, 2020 | -23.66M |
September 30, 2020 | -29.63M |
June 30, 2020 | -20.02M |
March 31, 2020 | -17.83M |
December 31, 2019 | -23.21M |
September 30, 2019 | -15.72M |
June 30, 2019 | -14.08M |
March 31, 2019 | -15.40M |
December 31, 2018 | -12.89M |
September 30, 2018 | -17.17M |
Date | Value |
---|---|
June 30, 2018 | -11.52M |
March 31, 2018 | -13.20M |
December 31, 2017 | -12.30M |
September 30, 2017 | -10.17M |
June 30, 2017 | -11.89M |
March 31, 2017 | -12.08M |
December 31, 2016 | -9.266M |
September 30, 2016 | -10.01M |
June 30, 2016 | -9.228M |
March 31, 2016 | -12.28M |
December 31, 2015 | -9.314M |
September 30, 2015 | -10.54M |
June 30, 2015 | -10.32M |
March 31, 2015 | -8.153M |
December 31, 2014 | -5.419M |
September 30, 2014 | -5.078M |
June 30, 2014 | 5.30M |
March 31, 2014 | -1.394M |
December 31, 2013 | -0.73M |
September 30, 2013 | -0.591M |
June 30, 2013 | -0.723M |
March 31, 2013 | -0.222M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-37.56M
Minimum
Jun 2021
-14.08M
Maximum
Jun 2019
-25.20M
Average
-23.66M
Median
Dec 2020
Free Cash Flow (Quarterly) Benchmarks
Karyopharm Therapeutics Inc | -18.58M |
Ardelyx Inc | -8.761M |
Minerva Neurosciences Inc | -5.991M |
Arcutis Biotherapeutics Inc | -56.25M |
4D Molecular Therapeutics Inc | -25.20M |